Please login to the form below

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. 

Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.

Clinical trials of emerging products, both alone and in combination, have delivered impressive evidence of improvements in durability and endpoints such as progression-free survival, and even overall survival. R&D pipelines are stuffed with immuno-oncology prospects across a wide range of indications.

To date, only a few immuno-oncology products have actually reached the market though. Two of them target the anti-PD1/PD-L1 pathway where much of the interest in immuno-oncology is currently invested.

Download and read part 1 of the complimentary whitepaper at:

6th January 2016



Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Chester House
Fulham Green
81-83 Fulham High Street
United Kingdom

Latest content on this profile

Live webinar: Optimise your digital assets with UX research
Thursday 25th October 2018 11:00 EDT / 16:00 BST / 17:00 CEST
Research Partnership
Rare diseases and orphan drugs: Our experience and expertise

Research Partnership
Conducting research for publication video

Research Partnership
Conference research case study
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Research Partnership
Portfolio analysis: Using market research to master communications across a therapeutic category

Research Partnership
EphMRA round up 2018
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Research Partnership